At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 40 enrolled
Drug / intervention
carfilzomib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II Trial of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma
In Brief
A Phase 2 clinical trial evaluating carfilzomib, pegylated liposomal doxorubicin (PLD), and 1 other intervention for Multiple Myeloma. Completed, enrolled 40 participants across 1 site.
Detailed Summary
The aim of this phase I/II trial is to determine the maximal tolerated dose (MTD) of carfilzomib together with pegylated liposomal doxorubicin hydrochloride (PLD) with or without dexamethasone, and then to establish the efficacy and safety of this novel combination in patients with relapsed or refractory multiple myeloma
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedNov 2010
Enrollment StartMay 2012
Primary CompletionDec 2017
Study CompletionMar 2018
TodayJul 2026
First PostedNov 23, 2010
Enrollment StartMay 14, 2012
Primary CompletionDec 28, 2017
Study CompletionMar 23, 2018
TodayJul 2, 2026
Enrollment to primary: 5.6 yearsPosted 15.6 years ago
Interventions
carfilzomibdrug
pegylated liposomal doxorubicin (PLD)drug
Dexamethasonedrug